CSF biomarkers reflecting the coexistence of amyloidosis and tauopathy, Aβ42/Aβ40 ratio and phosphorylated tau at threonine 181 (p-tau) respectively, allow one to claim the presence of AD-related neurobiology, independent of disease stage and clinical presentation [45]. This evidence concerns the gene MAPT and tauopathy.